孟鲁司特钠辅助治疗慢性阻塞性肺气肿患者对炎性因子及肺功能的影响

Effects of Adjuvant Therapy of Montelukast Sodium Treating Patients with Chronic Obstructive Pulmonary Emphysema(COPE) on Inflammatory Factors and Pulmonary Function

目的探讨孟鲁司特钠辅助治疗慢性阻塞性肺气肿(COPE)患者对炎性因子及肺功能的影响。方法选择2014年1月—2015年10月98例COPE患者为研究对象,采用随机数字表法分为观察组和对照组各49例。对照组给予布地奈德雾化吸入,观察组加用孟鲁司特钠辅助治疗,比较两组血清炎性因子与肺功能等指标。结果观察组血清中白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)含量分别为(130.53±12.96)ng/L、(22.54±6.36)ug/L、(91.27±11.65)pg/mL,明显低于对照组的(145.87±18.35)ng/L、(31.38±8.74)ug/L、(105.08±13.29)pg/mL(P<0.05);第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、最大肺活量(VC)及最大通气量(MMV)指标分别为(2.57±0.36)L、(3.16±0.19)L、(3.25±0.43)L、(70.57±6.15)L/min,均明显高于对照组的(1.93±0.45)L、(2.85±0.24)L、(2.73±0.37)L、(64.32±5.36)L/min(P<0.05),差异有统计学意义。结论孟鲁司特钠辅助布地奈德治疗有助于缓解慢性阻塞性肺气肿患者血清炎性因子表达水平,改善肺功能。

Objective To investigate the effects of adjuvant therapy of Montelukast Sodium treating patients with chron-ic obstructive pulmonary emphysema （COPE） on inflammatory factors and pulmonary function. Methods 98 cases of patients with COPE who were treated from January 2014 to October 2015 were selected as objects of study. The pa-tients were randomly divided into observation group and control group according to the random number table, with 49 cases in each group. Control group was treated with aerosol inhalation of budesonide, in addition to this, observation group was treated with adjuvant therapy of Montelukast Sodium. The serum inflammatory factors, pulmonary function and other indexes of the two groups were compared. Results The contents of serum interleukin-6 （IL-6）, interleukin-8 （IL-8） and tumor necrosis factor alpha （TNF-α） of observation group were（130.53±12.96）ng/L,（22.54±6.36）ug/L and （91.27±11.65）pg/mL respectively, all of which were significantly lower than those of control group, since the contents were respectively 145.87±18.35）ng/L,（31.38±8.74）ug/L and （105.08±13.29）pg/mL in control group（P〈 0.05）; the in-dexes of forced expiratory volume in 1 second （FEV1）, forced vital capacity （FVC）, vital capacity （VC） and maximum minute ventilation （MMV） were respectively （2.57 ±0.36）L, （3.16 ±0.19）L, （3.25 ±0.43）L and （70.57 ±6.15）L/min, all of which were significantly higher than those of control group, since the indexes were respectively （1.93±0.45）L,（2.85±＆amp;nbsp;0.24）L,（2.73±0.37）L and （64.32±5.36）L/min in control group （P〈 0.05）.the difference was statistically srgmifrecant. Conclusion Montelukast Sodium facilitating budesonide treatment is conducive to relieve serum inflammatory factor ex-pression level and improve pulmonary function of patients with COPE.